References
- IDF Diabetes Atlas. Fifth edition, 2011.
- Bliss MJJR. MacLeod and the discovery or insulin. QJ Exp Physiol 1989;74:87–96.
- Balkau B, Eschwege E. The diagnosis and classification of diabetes and impaired glucose regulation. In: Pickup JC, Williams G, editors. Textbook of diabetes, 3rd ed. Oxford: Blackwell Science; 2003. pp. 2.1–2.10.
- Stern J. Blood-sugar lowering effect of 1,1-dimethylbiguanide. Therapie 1958;13:650–9.
- Loubatiers A. The hypoglycemic sulphonamides: History and development of the problem from 1942 to 1955. Ann New York Acad Sci. 1957;71:4–11.
- Shamoon H, Duffy H, Fleischer N, Engel S, Saenger P, Strelzyn M, et al. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
- Turner RC, Holman RR, Cull CA, Stratton IM, Matthews DR, Frighi V, et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–53.
- Ryden L, Standl E, Bartnik M, den Berghe G, Bettridge J, de Boer MJ, et al. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. Europ Heart J. 2007;28:88–136.
- Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2009;52:17–30.
- Bonds DE, Miller ME, Bergenstal RM, Buse JB, Byington RP, Cutler JA, et al. The association between symptomatic severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study. Br Med J. 2010;340:b4909.
- Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, et al. Intensive blood glucose control and vascular outcomes in patients with Type 2 diabetes. N Engl J Med. 2008;358:2560–72.
- Del Prato S, La Salle J, Matthaei S, Bailey CJ. Tailoring treatment to the individual in type 2 diabetes practical guidance for the global partnership for effective diabetes management. Int J Clin Practice 2010;64:295–304.
- Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycaemia in type 2 diabetes: A patient-centered approach. position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577–96.
- Speight J, Conn J, Dunning T, Skinner TC, on behalf of Diabetes Australia. Diabetes Australia position statement. A new language for diabetes: Improving communications with and about people with diabetes. Diab Res Clin Pract. 2012;97:425–31.
- American Diabetes Association. Standards of medical care in diabetes—2013. Diabetes Care 2013;36:S11–S66.
- Gurzov EN, Eizirik DL. Bcl-2 proteins in diabetes: Mitochondrial pathways of β-cell death and dysfunction. Trends Cell Biol. 2011;21:424–31.
- Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–91.
- Huelgas RG, Diez-Espino J, Formiga F, Tejedor JL, Manas RL, Gonzales-Sarmiento E, et al. Treatment of type 2 diabetes in the elderly. Med Clin. 2013;140:134.
- Shin JA, Lee JH, Kim HS, Choi YH, Cho JH, Yoon KH. Prevention of diabetes: A strategic approach for individual patients. Diabetes Metabol Res Rev. 2012;28(Suppl. 2):79–84.
- Ceriello A. The emerging challenge in diabetes: The ‘metabolic memory’. VasculPharmacol. 2012;57:133–8.
- Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. Diabetologia 2013;56:686–95.